Table 2.

Changes in Serum Phosphorus, Calcium, and PTH Levels in Ferric Citrate and Active Control Participants Over 52-Week Active Control Study Period

	Mean Change From Baselinea					Adjusted Mean Differences Between Treatmentsb
	FC	AC	SC	CA	SC + CA	FC vs AC	FC vs SC	FC vs CA	FC vs SC + CA
Phosphorus (mg/dL)	–2.04 ± 1.99	–2.18 ± 2.25	–2.11 ± 2.31	–2.11 ± 1.92	–2.46 ± 2.52	0.01 (–0.30 to 0.33)	0.02 (–0.38 to 0.41)	0.05 (–0.46 to 0.57)	–0.04 (–0.64 to 0.57)
	n = 281; 189	n = 146; 113	n = 78; 63	n = 39; 28	n = 29; 22	P = 0.9	P = 0.9	P = 0.8	P = 0.9
Calcium (mg/dL)	0.22 ± 0.90	0.31 ± 0.95	0.17 ± 0.81	0.49 ± 0.96	0.41 ± 1.24	–0.12 (–0.28 to 0.04)	–0.08 (–0.27 to 0.12)	–0.25 (–0.52 to 0.02)	–0.04 (–0.35 to 0.27)
	n = 281; 189	n = 146; 113	n = 78; 63	n = 39; 28	n = 29; 22	P = 0.2	P = 0.5	P = 0.07	P = 0.8
PTH (pg/dL)	–167.1 ± 399.8	–146.5 ± 397.0	–134.3 ± 419.4	–98.9 ± 251.3	–244.5 ± 482.8	4.3 (–61.5 to 70.0)	–43.5 (–128.5 to 41.6)	58.1 (–53.4 to 169.6)	59.6 (–68.9 to 188.1)
	n = 247; 189	n = 133; 108	n = 72; 62	n = 35; 26	n = 26; 20	P = 0.9	P = 0.3	P = 0.3	P = 0.4

Abbreviations: AC, active control; CA, calcium acetate; FC, ferric citrate; SC, sevelamer carbonate; SC + CA, combination of sevelamer carbonate and calcium acetate; PTH, parathyroid hormone.

^aAnalyses performed using last-value-carried-forward imputation for missing measurements. Sample sizes indicate the number of patients with nonmissing baseline and follow-up data after the last-value-carried-forward imputation, followed by the sample size for patients with nonmissing baseline and 12-month follow-up measurements. Values present the mean change from baseline ± standard deviation.

^bShown are the estimated mean differences (95% confidence interval) in change from baseline to 12 months between the indicated treatment groups after adjustment for baseline measurement of the outcome variable. All P values for comparisons of active control subgroups with each other (CA vs SC, CA vs SC + CA, SC vs SC + CA) were > 0.05.